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ABSTRACT 
Background: Negative influences from psoriasis is evident. In China, quality of life in psoriasis 
patients seeking care in hospitals has not been yet fully studied before. Finding out associated 
factors for health-related quality of life would facilitate the health intervention and resource 
allocations. 
Aims: To estimate health-related quality of life for psoriasis patients in China and to explore the 
effect of demographic, life style, clinical factors on quality of life.  
Materials and methods: This cross-sectional study involved 1258 psoriasis patients from 9 
medical centers in China. Demographic factors, life style factors, and clinical factors were 
reported by patients themselves or doctors along with Dermatology Quality of Life Index 
questionnaire to assess the quality of life in psoriasis. Scores of quality of life measure were 
dichotomized as ≤10 to represent less affected quality of life and >10 to represent largely affected 
quality of life. Descriptive analysis was used to summarize the data. Logistic regression models 
were used to explore the association between quality of life and risk factors. 
Results: In serious (OR 3.50; 95% CI [1.11-10.98]; P=0.035) and severe severity (OR 7.25; 95% 
CI [1.29-40.69]; P=0.029) by physician global assessment were associated with largely affected 
quality of life. Having exercise habit was associated with lower risk of having largely affected 
quality of life (OR 0.74; 95% CI [0.56-0.97]; P=0.035). These results were adjusted by having or 
not a medical insurance.  
Conclusion: Severity is the most significant risk factor for largely affected quality of life, along 
with having medical insurance and no exercise habit. Policy makers should focus on critical 
conditioned patients and be cautious about the possible negative effect from medical insurance 
and physical inactivity.  
 
Key words: Psoriasis, Health-related quality of life (HRQOL), China, hospital patients, 
determinants, cross-sectional study 
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ABBREVIATION 
 
HLA: Human leukocyte antigen 
TCM: Traditional Chinese Medicine 
PASI: Psoriasis Area and Severity Index 
BSA: Body Surface Area 
PGA: Physician Global Assessment 
WHO: World Heath Organization 
QOL: Quality of Life 
HRQOL: Health-Related Quality of Life 
DLQI: Dermatology Quality of Life Index 
PDI: Psoriasis Disability Index 
PQOL-12: Psoriasis Quality of Life 12 items 
SF-36: Short-Form Health Survey Questionnaire 
WHOQOL-BREF: World Health Organization Quality of Life-BREF questionnaire 
RMB: Renminbi, Chinese yuan (Chinese official currency: ¥) 
BMI: Body Mass Index 
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INTRODUCTION  
Overview of psoriasis 
Psoriasis is manifested with erythematous papules or thickened plagues covered with silver-white 
scales. It causes daily life inconvenience like pruritus, burning sensation, dryness in the inflicted 
area. Negative influence on appearance like exfoliating epidermal residues, crumbled and 
pigmented fingernails are the biggest complaints. Based on the morphology and distribution of 
the symptoms, psoriasis can be categorized as several subtypes: plague psoriasis, inverse 
psoriasis, guttate psoriasis, erythrodermic psoriasis, generalized pustular psoriasis, and 
palmoplantar psoriasis (1). The most common one is plague type, which highlighted with red 
patches and silver scales; inverse psoriasis happens on any area where two patches meet together, 
such as groin and abdominal folds; guttate psoriasis is more common in youngsters and children, 
with eruption of round oval shaped papules no bigger than 1 cm; erythrodermic psoriasis refers to 
symptoms that diffuse to more than 90% of the body; generalized pustular psoriasis is the most 
dangerous form featured with clustered blister, pustules followed by fever and infection; 
palmoplantar psoriasis involves palms and soles. Painful joints from inflammatory arthritis 
especially on knees and elbows may also occur. Pathological reasons for psoriasis are not fully 
understood. Genetic mutation on chromosome 1q, 2q, 7q, 6q, 8q, that normally modulate 
keratinocyte differentiation and development, are proven to increase the susceptibility for 
psoriasis, though exact pattern of inheritance is not clear. Human leukocyte antigen (HLA) gene 
region falls within these aberrant chromosomes that mediates the immune cells functions, 
suggesting immune response deregulation is the major pathogenesis in psoriasis. (2)  
 
Current treatment in standard medicine ranges from topical corticosteroid to human monoclonal 
antibody, immunosuppressants and phototherapy. While treatments in outpatient setting is quite 
enough for most patients, some patients having a sudden flare-up or in critical condition will need 
to be hospitalized. (3) Inpatient setting will offer more rigorous regimen of topical corticoid, 
systemic biological agents, or UV lights. The cost of management of psoriasis is often enormous 
due to life-long use of drugs and higher price from advanced therapy. In China, despite the 
mainstream western treatment, many resort to Traditional Chinese Medicine (TCM) including 
herbal drugs and acupuncture. (4) A combination of western medicine and Traditional Chinese 
Medicine is common in clinical practice throughout the country.   
!
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Epidemiology of psoriasis 
Prevalence of psoriasis in different countries varies from 0.09% (5) to 11.4% (6). In 
industrialized countries, it ranges between 1.5% to 5% (7). Most cases happen in adults but can 
also occur on children. Age onset of psoriasis are often between 15 to 30 years old. Early onset of 
psoriasis (before or equal to 40 years old) is proposed to be attributable to HLA gene, and late 
onset of psoriasis (after 40 years old) is lacking HLA association, though this bimodality is not 
observed in every study (8). Epidemiology data indicates psoriasis is most common among 
Northern Europe population and the least in eastern Asia population. (9) This is in line with the 
result of gene polymorphism analysis showing that Asian are less likely to develop psoriasis 
compared to Caucasian (10). In a study from United States, Caucasians have twice higher 
prevalence of psoriasis than Black, Hispanic, and other ethnic groups (11). In China, there are 
few epidemiological studies for psoriasis but they are either outdated (12) or sampling in mostly 
the rural areas (13). Large scale multicenter study in 2012 (13) shows prevalence of psoriasis is 
0.47% nationwide, with 0.54% for men and 0.44% for women.   
 
Severity measurement of psoriasis 
There are many ways to examine psoriasis severity. Psoriasis Area and Severity Index (PASI) is 
perceived as a gold standard. It uses standardized mathematic formula with each factors weighted 
to produce the total score by taking into account the body surface area (BSA) involvement, lesion 
location, the extent of redness and thickness. However, PASI has limitation because of the 
insensitivity to small affected body surface area and variability on measuring body surface area 
(14). These drawbacks limit its use in clinical practice and reproducibility. Dispute about whether 
PASI serves as single indicator for psoriasis severity remains inconclusive among clinicians.  
 
European Medicines Agency recommended examining the improvement of Physician Global 
Assessment (PGA) along with PASI to determine psoriasis severity in a clinical trial (15). PGA 
has been applied for various diseases in the clinical assessment due to its simplicity. It is a 
subjective evaluation relying on doctor’s judgments on lesions characteristics without 
considering how much body surface areas involved or where the lesion is. Such way to evaluate 
the severity, though a little abstract, is in parallel with clinical practice that meticulous measures 
!
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on characteristics of psoriatic lesions are seldom performed and often replaced with crude 
observation. The validation of PGA is not widely done, but some studies suggest it has sound and 
validated in psoriasis study (16,17). However, there is no standardized version of PGA. Multiple 
items form (i.e. the extent of erythema, plague elevation, scale were specified) or single item 
form (i.e. final score assigned without lesion traits specified) are both available and no consensus 
has been made for scoring scale for PGA. Clinical workers often choose among 5 points, 6 points, 
and 7 points according to how detailed the severity needs to be described in the interested study. 
But the method for rating is the same: lowest score represents “clear condition” or “slight” and 
the highest score is “serious” or “severe”.  
 
Quality of Life and Health Related Quality of Life definition 
World Health Organization defined quality of life (QOL) as ‘‘the individuals’ perception of their 
position in life, in the context of the cultural and value systems in which they live and in relation 
to their goals, expectations, standards and concerns (18).’’ The description implies the 
importance of subjective experience to quality of life rather than healthcare worker’s observation. 
In clinical practice, subjective assessment of quality of life is often not in line with the 
improvement of clinical parameters. Patients with similar severity of diseases usually have 
different opinions about their own quality of life. Therefore, instead of observant evaluation, self-
reporting assessment becomes the mainstay method to measure QOL. On the other hand, the term 
“Health-Related Quality of Life (HRQOL)” specifically indicates the quality of life under 
disabilities, disorders, or diseases. It differs from the concept of general QOL in a sense that 
HRQOL focuses more on the aspects that are influenced by health status or that can influence 
health status. Without the absolute definition, HRQOL is commonly perceived as a collected 
result from physical, psychological, and social dimension. In clinical practice, it has increasingly 
become crucial for its usefulness on allocating resources or determining clinical trial endpoint.  
 
Health-Related Quality of Life (HRQOL) components 
The conceptual framework in Figure 1 is adapted from Wilson and Cleary model of HRQOL (19). 
It roughly explains how various factors affect and interact with HRQOL for psoriasis patients. 
The variables available in the dataset are highlighted in red while the aspects captured in this 
study’s HRQOL measurement are highlighted in blue. It is hard to identify a single pathway 
!
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about how each factor leads to the quality of life. Individual characteristics increase the 
likelihood to develop a disease and also interact with clinical factors to disrupt quality of life. 
Environmental characteristics relate to how a person with psoriasis fit into the surroundings and 
influence how well the patient cope with the disease. Clinical factors decide the exact disease 
status and meanwhile interact, associate with individual and environmental factors. Individual 
and environmental characteristics also interact with each other. 
 
Age and gender are linked to the psoriasis quality of life with elder people experiencing higher 
psychological stress and females having more anxiety and depression (20). Ethnicity difference in 
quality of life impact is observed in the previous study where non-Caucasians are shown to feel 
more impact from the disease than Caucasians do (20,21). Emotional support can be provided by 
marriage to deal with mental stress from skin diseases (23). Income and medical insurance 
correlates to the health care patients received, hence affects the severity of disease. Having better 
income and insurance also helps personal satisfaction and mental preparedness for the disease. 
Education could help to achieve better skin disease intervention (24) and low education level is 
inclined to have lower self-perceived health (25). Overweight is correlated with high psoriasis 
severity (26,27) and alters a patient’s feeling by influencing the self-conception of body image. 
Tobacco use is a known triggering factor for psoriasis by facilitating the inflammation and it has 
previously shown to be associated with higher clinical severity in psoriasis (28,29,30). Heavy 
alcohol intake is reportedly a aggravating factor for inflamed skin diseases (31) by stimulating 
production of pro-inflammatory factors (32). Continued drinking interferes with treatment 
compliance (33). Exercise helps weight control thus helps psoriasis healings and facilitate the 
stress reduction (34). Psoriasis incidence relates to geographical region (7) and different climate 
in different provinces influences how often the symptoms flared up (35). Clinical factors are the 
major components determining the extent of disability and directly impair patients emotion and 
social function. Long duration of disease is associated with more anger and shame (36); early 
onset of psoriasis has shown to cause more interpersonal difficulties than late onset patients (37); 
overall severity suggest how strong the itchy and pain feeling is; psoriasis patients are found at 
higher risk to develop common comorbidities such as cardiovascular disease and diabetes (38), 
both of which add up the disease burden (37,38). 
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Figure 1 Conceptual framework for Health-Related Quality of Life in psoriasis patients 
Red: the variables available in the dataset 
Blue: the aspects captured in this study’s HRQOL measurement.!
!
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Health-Related Quality of Life (HRQOL) instruments 
When it comes to dermatology, there are 3 kinds of HRQOL instruments available: generic 
instruments, dermatology specific instruments, and condition specific instruments (41). Generic 
instrument can be used for any general disease, irrespective of the types of illness or conditions, 
eg. World Health Organization Quality of Life (WHOQOL), Short Form Health Survey (SF-36). 
Dermatological specific instruments are suitable and valid for skin diseases only, eg. 
Dermatology Quality of Life Index (DLQI), Skindex 16, Skindex 29. Condition specific 
instruments are only for comparison between patient groups who have same diagnosis, eg. 
Psoriasis Disability Index (PDI), Psoriasis Quality of Life-12 Items (PQOL-12). The choice of 
instruments depends on the interests of researchers and the aim of the study. If used in other 
countries, different language versions of HRQOL questionnaires need to go through backward 
and forward translation and tested before they used for the research. DLQI is the most commonly 
used HRQOL instrument in dermatology. Mandarin Chinese version of DLQI in previous 
research has shown reliability (internal consistency, Cronbach’s α is 0.91) and established 
convergent validity by spearman correlation (r=0.77 correlated with Psoriasis Disability Index 
and r=-0.35 to -0.56 correlated with SF-36) and confirmatory factor analysis (42). A 5 points 
improvement in DLQI is considered the minimum efficacy goal in treatment (43). Some 
guidelines perceive DLQI above 10 together with PASI as the criterion for a psoriasis patient to 
be treated with a biological agent (42,43).   
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BACKGROUND 
Skin condition is one of top 20 leading health burden worldwide and ranks 4th on non-lethal 
causes in years lost due to disability (46). Psoriasis is a chronic inflammatory skin disease that 
causes physical and psychological stress. In western countries, psoriasis prevalence ranges 
between 2% and 3% (7). Low and middle income countries mostly has psoriasis prevalence 
below 0.5% (7). Most epidemiological data of psoriasis are from high income countries, 
suggesting a huge knowledge gap from low and middle income countries. The insufficient supply 
of dermatologist in low-middle income countries worsens the quality of life in such patients (9). 
Unlike most systemic chronic diseases that affect health internally and subtly, psoriasis patients 
suffer from disrupted outlook, interpersonal difficulties, and disabled social functions. The 
quality of life of such patients is not solely constructed by clinical conditions. World Health 
Organization (WHO) recognizes the needs to have multilateral management of psoriasis (9) that 
looks beyond the physical illness and the efforts to establish the factors behind the poor quality of 
life. Some studies have researched about quality of life in psoriasis patients in China before but 
they focus a lot on clinical trial setting and are in small scale (45,46). By understanding psoriasis 
patients’ quality of life and its determinants, it helps policy makers to allocate the intervention 
resources on different patient groups. In this study, we seek to investigate quality of life in 
psoriasis patients in China and its association with demographic, life style, and clinical factors. 
 
RESEARCH QUESTIONS 
What are the associated factors for quality of life in psoriasis patients in China? 
 
Aim 
To describe the health- related quality of life in psoriasis patients in China, and to explore the 
relationship between their health-related quality of life and risk factors. 
 
Specific objectives 
1)! To describe and compare the health related quality of life among the psoriasis patients in 
China who have different demographic, life style, and clinical factors.  
2)! To explore whether demographic, life style, clinical factors are associated with health 
related quality of life in psoriasis patients in China.   
!
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METHODOLOGY 
Study design 
This is a cross-sectional study based on secondary data from a hospital-based survey done in 9 
medical centers in China between July 2013 and September 2015. The survey was conducted at 
doctor visits or inpatient stay, collecting dermatological patients’ demographic, clinical profile, 
and life style facts. 4 HRQOL questionnaires (DLQI, Skindex 16, Skindex 29, WHOQOL) were 
also given to the participants. Dermatology Quality of Life Index (DLQI) was chosen as our 
outcome measure. 
 
DLQI questionnaire consists of 10 items measuring how much the skin problem has affected 
several aspects of life over the past week, with each item rating from 0 to 3. The questions can be 
categorized in six domains: symptoms and feelings (Question 1 and 2), daily activities (Question 
3 and 4), leisure (Question 5 and 6), work and school (Question 7), personal relationship 
(Question 8 and 9), treatment-caused burdens. (Question 10) Appendix A shows the template of 
DLQI questionnaire in English. Appendix B has the scoring guideline and instruction of use for 
DLQI. Question formats are “Over the last week, how bothering (itchy, painful, stinging) has 
your skin been?” or “over the last week, how much has the skin problem made it difficult for a 
certain activity (eg. home, school, sports, sexual activity)?” Possible answers are : 0 (“not at all”) 
or (“non-relevant”), 1 (“a little”), 2 (“a lot”), 3 (“very much”). The total score is calculated by 
summing up score of each question, generating a range of possible values from 0 to 30. The total 
score could also be expressed by percentage out of 30. Higher the total score, the poorer the 
quality of life. Besides, each domain has subscale that can be scored separately. In the incomplete 
questionnaires, if there is only one unanswered item, it will be replaced as 0 and included in the 
sum-up. Question number 7 has two parts. First the patients were asked whether the disease has 
prevented them to go to work or school. If yes, it is scored as 3. If no, patients are then asked how 
much the skin problems affects work or school. “A little” is scored as 1 and “a lot” is scored as 2. 
If two or more questions are left unanswered, the questionnaires will be considered invalid.  
!
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Study setting
 
Nine medical centers participated in this study: 3 from Beijing city, 1 from Heilongjiang province, 
1 from Shanghai city, 1 from Xinjinag province, 1 from Sichuang province, 2 from Guangdong 
province. Figure 2 shows the list of attended hospital and the number in parenthesis indicates the 
how many patients from each site were included in the final analysis.  
 
  
(124) Longhua Hospital Shanghai 
University of Traditional Chinese Medicine 
(128) Guanganmen Hospital, China 
Academy of Chinese Medical Science  
(72)%Chinese-Japan Friendship Hospital 
(264)%Beijing Hospital of 
Traditional Chinese Medicine%
(355)%Traditional Chinese 
Medicine Hospital of Xinjiang 
autonomous region!
(47) Chengdu University of Traditional 
Chinese Medicine Affiliated Hospital 
(19) The First Affiliated Hospital of 
Guangzhou University of Chinese 
Medicine 
(132)%Heilongjiang Traditional Chinese 
Medicine Academy of Sciences!
(117) Guangdong Provincial Hospital of Traditional 
Chinese Medicine 
 
Figure 2 participated hospitals and the number of patients each contributed 
!
!
!
10 
Sampling criteria 
These 9 medical centers from different provinces were selected based on cluster sampling method. 
All patients were eligible to participate if they were confirmed with diagnosis of any 
dermatological diseases, absence of severe mental illness, and were able to answer the 
questionnaires by themselves. As many as 10,042 patients completed the questionnaires, where 
1,314 of them have psoriasis as one of the diagnosis. Psoriasis patients below 16 years old or 
having two or more questions unanswered in their DLQI questionnaires were then excluded. The 
final dataset contains 1,258 psoriasis patients. The selection process is illustrated in Figure 3. 
 
 
 
  
1) Exclude patients below 16 years old, n=26  
2) Excluded invalid DLQI results (2 or more items unanswered), n=30 
10042 skin disease patients 
1314 diagnosed with unspecified psoriasis  
1258 eligible psoriasis patients 
Exclude those without psoriasis as diagnosis, n=8782 
Figure 3. Selection process for data analysis 
!
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Data collection 
Survey questionnaires and HRQOL questionnaires were completed by participants.  
Self-reported variables from patients are as follows:  
1)! Demographic factors: age, gender, weight, height, marital status, type of department, location 
of sampled medical center, living city, ethnicity, food preference, education level, medical 
insurance type, occupation, income, money spent in outpatient and inpatient departments, 
average frequency of outpatient visits per month, average frequency of inpatient visit last year, 
having comorbidities or not, specific comorbidities.   
2)! Life style: whether or not have habits of smoke, alcohol, exercise and their amounts.  
3)! Generic and dermatology specific health related quality of life questionnaires. (Skindex16, 
Skindex29, DLQI, WHOQOL)   
Doctors were responsible for other clinical aspects variables like diagnosis, duration of the 
disease, and physician global assessment for severity. The food preference, occupation, type of 
visit, frequency of any types of visit during last year or last month were excluded in the 
descriptive and regression analysis for its irrelevance to cause on the quality of life in psoriasis. 
Specific comorbidities are collected but excluded in the study due to the low frequency of each 
specific comorbidity.  
 
Variable selection and definition 
Variables were selected in this study due to their correlation with the quality of life based on 
literature research or theoretical association. Variables included in the crude analysis were age, 
gender, marital status, region, ethnicity, educational level, having medical insurance or not, 
income above 4000 RMB (Chinese Yuan) or not (around 5000 Swedish kronor), Body Mass 
Index (BMI), duration of disease, severity, having comorbidities or not, drinking alcohol habit, 
smoking habit, exercise habit. The categorization of variables was established on rationale of 
literature research or the purpose to evenly distribute samples. Detailed grouping rationales and 
variables definition are explained as follows:   
1)! Quality of Life: Total scores of Dermatology Quality of Life Index were calculated by adding 
up the score of every item in DLQI. Scores>10 were considered largely affected quality of 
life, indicating worse life quality; scores≤10 were defined as less affected quality of life, 
indicating better life quality (43,47). 
!
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2)! Risk factors: 
a)! Age was classified as young adults (16-35 years old), middle age (36-65 years old) 
and elder people (more than 65 years old) (50). 
b)! Age onset was calculated by age minus disease duration expressed by years. In line 
with clinical definition (51), early onset psoriasis was defined as ≤40 years old and late 
onset psoriasis was >40 years old.  
c)! Body Mass Index (BMI) was calculated through dividing weight in kg by square of 
height in meters and BMI interval was defined (52) as underweight (≤18.50 kg/m2), 
normal (18.51-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obese (≥30.0 kg/m2).  
d)! Regions were regrouped based on location of medical centers instead of patient 
residence since all participants live within the province where their hospitals situate. 
Heilongjiang province and Beijing city were categorized as northern area, Guangdong 
as southern area, Shanghai as eastern area, Xinjiang and Sichuang as western area.  
e)! 4000 RMB of income was the mean of entire samples thus has been chosen as a cutoff 
criterion. 
f)! Marital status was collected as married, single, divorced or separated, widowed and 
regrouped as married or not married.  
g)! The possession of medical insurance was originally collected as no medical insurance 
and different types of insurance: public funded medical insurance, urban employee 
medical insurance, urban residence medical insurance, rural medical insurance, 
poverty help, commercial medical insurance.  
h)! Duration of disease was recorded in month. We later calculated them as years and 
rounded up to the nearest integer with 1 decimal.  
i)! Severity of disease was assessed by physician global assessment with 5 points scale 
from 1 to 5, corresponding to “slight” “mild” “moderate” “serious” “severe”.  
j)! Comorbidity was defined as systematic chronic diseases. Co-existing skin problems 
were not counted as comorbidities.  
k)! Whether having exercise habit and its amount were answered liberally by patients. We 
defined the habitual exercise as “regular activity”: at least one time per week and at 
least 30 minutes each time (53). 
!
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l)! Whether having drinking habit and its amount were answered liberally by patients. 
The amount was collected as at least 1 drink in a year, in a half year, in a month, in a 
week and everyday. We defined habitual drinking as at least 1 drink averagely per 
week due to low availability in daily drinker and excessive omission of consumption 
amount.  
m)!Whether having smoking habit and its amount were answered liberally by patients. We 
defined habitual smoking as “daily smoker”: at least 1 cigarette everyday (53). 
 
Data Management 
All data was recorded in Microsoft Excel file in Mandarin, later translated into English, then 
imported into SPSS software, SPSS version 22 (SPSS, Inc., Chicago, IL). Missing values in 
DLQI questionnaires were considered “not answered” or “not applicable”. For example, second 
part of question number 7 in DLQI is not applicable if first item is answered, and vice versa. In 
the situation where double entry is found in question number 7, first part’s answer is chosen to 
represent the correct value. If values of both parts are missing, number 7 is considered not 
answered. For single unanswered question in DLQI, a score of 0 was imputed. Any person who 
left 2 or more than 2 unanswered questions in DLQI was eliminated from the dataset. Minimum 
value recorded was assumed for those who claimed to have exercise and smoking habit but failed 
to report the consumption amount. Samples with any variable having missing values remained in 
the dataset since missing values in each variable were all below 10%, except 13.1% missing 
values were observed in income level.  
 
Statistical analysis 
All statistical analysis was performed with SPSS version 22 (SPSS, Inc., Chicago, IL) 
Descriptive statistics were performed: mean, standard deviation and median were used for 
summarizing numerical variables, and frequencies and percentages for the categorical variables. 
Histogram, Q-Q plot and Kolmogorov-Smirnov test are used to examine the normality of DLQI 
scores distribution. DLQI scores were then dichotomized as above 10 and below 10 to represent 
largely affected quality of life and less affected quality of life. Chi-square test were used to 
compare the distribution of categorical variables among people with DLQI above 10 or below 10. 
Mann Whitney test was used to determine the difference for non-normal distributed continuous 
!
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variables in two groups. Univariate and multivariable binary logistic regression were used with 
95% confidence interval to determine the association between risk factors and DLQI above 10. 
Crude and adjusted odds ratios were calculated. Variables with p-value smaller or equal to 0.25 in 
univariate logistic regression were candidates to be included in multivariable logistic regression. 
Enter, backward, forward methods in multivariate regression were all used and only results from 
backward selection method is presented. Cluster effect within each hospital was taken into 
account and included in the final multivariable regression analysis. Missing data in the final 
model were handled with listwise deletion method: participants with any missing value in any 
variable were excluded in multivariable regression (n=1,121). Final model only included 
statistically significant variables. P-values less than 0.05 were considered significant.  
 
Ethical consideration 
The use of dataset was agreed by lead research group in Guangdong Provincial Hospital of 
Traditional Chinese Medicine, which Dr. Ze-Hui He affiliates with. Before questionnaire 
administration, written informed consent was collected by patients’ physicians along with oral 
explanation to each participant. The ethics committee in Guangdong Provincial Hospital of 
Traditional Chinese Medicine approved the study, along with the approval from ethics 
committees in other 8 participated hospitals.  
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RESULTS 
Study group profile 
The demographic profile of study population is shown in Table 1. Of 1,258 participants most 
people were from outpatient department, and the majority was below 65 years old. There were 
59.1% male and 40.9% female. Most patients were married (70.3%), living in Northern China 
(47.4%) and Western China (32.0%), and were Chinese descents (96.0%). There were 80.1% of 
patients having college or even higher education degree. There were 80.4% of patients currently 
having medical insurance, and 70.6% of patients with monthly income lower than 4000 RMB 
(equal to around 5000 SEK). While only 6.9% were considered obese, 50.6% of our study 
population had normal BMI. More than 80% of patients started to experience psoriasis symptoms 
before 40 years old. Half of people had disease duration under or equal to 7 years. Severity of 
psoriasis was mostly at moderate level (54.0%) and mild level (22.0%) assessed by physician 
global assessment. Few had severe (2.3%) or slight level (2.4%) of psoriasis. Almost half of 
patients (41.0%) were living with at least one kind of coexisting systematic diseases. The 
majority didn’t have habit of drinking alcohol (67.9%) and smoking (63.4%) but 55.0% of them 
had exercise habit for at least 30 minutes per week.  
 
Descriptive analysis 
From Table 1, the study population had 605 largely affected people (48.1%) and 653 less affected 
people (51.9%). The proportions of DLQI score above 10 were significantly different in medical 
insurance status (p=0.001), severity of disease (p<0.001), and exercise (p=0.02). People with 
insurance had 12% more with worse quality of life than people without insurance. People with 
severe disease had 44% more to have worse quality of life than those in slight disease. People 
without exercise habit had 6.5% more to have worse quality of life than those exercise regularly. 
Median duration of disease was 8 years in people with DLQI>10, significantly different than 6 
years in people with DLQI≤10 (p=0.001).  
!
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Table 1 Characteristic of 1258 psoriasis patients from medical centers and association between demographic factors, 
clinical factors, life style factors, and the proportion of DLQI>10 in each group 
Factors Number of patients  (% in valid cases) 
DLQI >10 
(% in subgroup) 
n=605 
DLQI≤10  
(% in subgroup) 
n=653 
X2 P!
Demographic factors      
Age 16-35 years old 643 (51.1) 304 (47.3) 339 (52.7) 0.98 0.61 
 36-65 years old 571 (45.4) 282 (49.4) 289 (50.6)   
 >65 years old 44 (3.5) 19 (43.2) 25 (56.8)   
Gender Male 737 (59.0) 361 (49.0) 376 (51.0) 0.48 0.48 
 Female 513 (41.0) 241 (47.0) 272 (53.0)   
Marital 
status Unmarried 369 (29.7) 177 (48.0) 192 (52.0) 0.002 0.96 
 Married 875 (70.3) 421 (48.1) 454 (51.9)   
Regions Northern 596 (47.4) 288 (48.3) 308 (51.7) 2.06 0.559 
 Southern 136 (10.8) 58 (42.6) 78 (57.4)   
 Eastern 124 (9.9) 63 (50.8) 61 (49.2)   
 Western 402 (32.0) 196 (48.8) 206 (51.2)   
Ethnicity Not Chinese 
Han 
48 (4.0) 23 (47.9) 25 (52.1) <0.001 0.99 
 Chinese Han 1165 (96.0) 559 (48.0) 606 (52.0)   
Education 
level below college 249 (19.9) 118 (47.4) 131 (52.6) 0.06 0.79 
 College and higher 1000 (80.1) 483 (48.3) 517 (51.7)   
Medical 
insurance 
No 233 (19.6) 89 (38.2) 144 (61.8) 10.46 0.001 
 Yes 956 (80.4) 478 (50.0) 478 (50.0)   
Income level ≤4000 RMB 777 (70.6) 376 (48.7) 396 (51.3) 0.48 0.82 
 >4000 RMB 321 (29.4) 154 (48.0) 167 (52.0)   
!
(continue to the next page)  
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(continued from table 1) 
Factors Number of patients  (% in valid cases) 
DLQI >101 
(% in subgroup) 
n=605 
DLQI≤10  
(% in subgroup) 
n=653 
X2 P 
Clinical related factor      
BMI2 Underweight  104 (8.6) 46 (44.2) 58 (55.8) 2.25 0.52 
 Normal 683 (56.4) 318 (46.6) 365 (53.4)   
 Overweight 340 (28.1) 173 (50.9) 167 (49.1)   
 Obese 83 (6.9) 39 (47.0) 44 (53.0)   
Age onset ≤40 years old 987 (83.0) 483 (48.9) 504 (51.1) 1.59 0.20 
 >40 years old 202 (17.0) 89 (44.1) 113 (55.9)   
Duration of the disease (year)3 7 (2.4-13.3) 8 (3.0-15.0) 6 (2.0-13.0)  0.001§ 
Severity Slight 29 (2.4) 9 (31.0) 20 (69.0) 55.24 <0.001 
 Mild 272 (22.4) 88 (32.4) 184 (67.6)   
 Moderate 654 (54.0) 319 (48.8) 335 (51.2)   
 Serious 229 (18.9) 141 (61.6) 88 (38.4)   
 Severe 28 (2.3) 21 (75.0) 7 (25.0)   
Comorbidity No 724 (58.6) 334 (46.1) 390 (53.9) 2.07 0.15 
 Yes 511 (41.4) 257 (50.3) 254 (49.7)   
Life style factors      
Smoking4 No 802 (63.7) 374 (46.6) 428 (53.4) 1.88 0.17 
 Yes 456 (36.3) 231 (50.7) 225 (49.3)   
Alcohol5 No 1173 (85.1) 561 (47.8) 612 (52.2) 0.49 0.48 
 Yes 85 (14.9) 44 (51.8) 41 (48.2)   
Exercise6 No 581 (45.0) 300 (51.6) 281 (48.4) 5.43 0.02 
 Yes 677 (55.0) 305 (45.1) 372 (54.9)   
1 DLQI>10: largely affected quality of life (worse quality of life); DLQI≤10: less affected quality of life (better 
quality of life) 
2 in kg/m2, definition for interval is: underweight ≤18.50 kg/m2, normal 18.5-24.9 kg/m2, overweight 25.0-29.9 
kg/m2, obese ≥30.0 kg/m2 
3 expressed as continuous variable and median with interquartile range in overall population 
§ result of Mann Whitney test comparing median disease duration between DLQI>10 and ≤10 
4 at least 1 cigarette everyday. 
5 at least 1 drink averagely per week 
6 at least one time per week and at least 30 minutes each time. 
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Regression analysis 
 
Table 2 shows the crude odds ratio and adjusted ratio from logistic regression analysis for risk 
factors and DLQI>10. In univariate analysis, factors associated with DLQI above 10 were: 
having medical insurance (OR 1.62; 95% CI [1.12, 2.17]; p=0.001), 1 year longer duration of 
disease (OR 1.02; 95% CI [1.0, 1.03]; p=0.003), serious level of disease (OR 3.56; 95% CI [1.55-
8.17]; p=0.003), severe level of disease (OR 6.67; 95% CI [2.08-21.31]; p=0.001), and having 
exercise habit (OR 0.78; 95% CI [0.62, 0.97]; p=0.03).  
 
In multivariable analysis, regions, insurance, BMI, age onset, duration, severity, comorbidities, 
exercise habits were selected into the stepwise model. After backward selection, the significant 
associated factors to quality of life were: having medical insurance (OR 1.58; 95% CI [1.11-2.25]; 
p=0.017), serious disease (OR 3.50; 95% CI [1.11-10.98]; p=0.035), severe disease (OR 7.25; 
95% CI [1.29-40.69]; p=0.029), and having exercise habits (OR 0.74; 95% CI [0.56-0.97]; 
p=0.035)  
!
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Table 2 Crude and adjusted odds ratios (OR) from regression analysis for association between demographic, life style, and 
clinical factors with DLQI>10 by using 1258 psoriasis patients in hospital-based data 
 
 
Table 2.  Logistic regression analysis for the probability to have severe impairment of life quality in psoriasis patients 
Variables Category 
OR (95% CI) 
Crude P Adjusted1 P 
Age (years) 16-35 1    
 36-65 1.09 (0.86-1.36) 0.46   
 Above 65 0.84 (0.45-1.57) 0.60   
Gender Male 1    
 Female 0.92 (0.73-1.15) 0.48   
Marital status Unmarried 1    
 Married 1.00 (0.78-1.28) 0.96   
Regions Northern 1    
 Southern 0.79 (0.54-1.15) 0.23   
 Eastern  1.10 (0.75-1.62) 0.61   
 Western 1.02 (0.79-1.31) 0.89   
Ethnicity Not Chinese Han 1    
 Chinese Han 1.00 (0.56-1.78) 0.99   
Education level Below college 1    
 College or higher  1.04 (0.78-1.37) 0.79   
Medical insurance No 1  1  
 Yes 1.62 (1.21-2.17) 0.001 1.58 (1.11-2.25) 0.017 
Income level ≤4000 RMB 1    
 >4000 RMB 0.97 (0.74-1.26) 0.83   
BMI Underweight  1    
 Normal 1.10 (0.73.-1.66) 0.65   
 Overweight  1.30 (0.84-2.03) 0.24   
 Obese 1.12 (0.62-1.99) 0.70   
Age onset ≤40 years old 1    
 >40 years old 0.82 (0.60-1.11) 0.20   
Duration of the disease § Years 1.018 (1.0-1.03) 0.003   
Severity by physician global 
assessment 
Slight 1  1  
Mild 1.06 (0.46-2.42) 0.88 1.09 (0.29-3.97) 0.88 
Moderate 2.11 (0.94-4.71) 0.067 1.95 (0.54-7.02) 0.26 
Serious 3.56 (1.55-8.17) 0.003 3.50 (1.11-10.98) 0.035 
Severe 6.67 (2.08-21.31) 0.001 7.25 (1.29-40.69) 0.029 
Comorbidities No 1    
 Yes 1.18 (0.94-1.51) 0.135   
Smoking No 1    
 Yes 1.19 (0.77-1.23) 0.84   
Alcohol No 1    
 Yes 1.71 (0.75-1.82) 0.48   
Exercise No 1  1  
 Yes 0.77 (0.61-0.95) 0.02 0.74 (0.56-0.97) 0.035 
Variables included in multivariate analysis (P≤0.25) are highlighted in grey color.  § expressed as continuous variable 
1 Final multivariate model is adjusted for medical insurance, severity by physician global assessment, and exercise.  
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DLQI in different severity groups 
To look into the extent of quality of life affected by different severity, we formulated graph 1 to 
present the mean scores of six domains of DLQI for people with different severity (values are 
attached in Appendix C). Numbers in parenthesis indicated the maximum score of each subscale. 
Significant different scores (p<0.05) in each domain were observed. The highest score in any 
domain always belonged to people with the severe disease. The lowest score in any domain 
mostly belonged to people with the slight disease, except mild disease group scored the lowest in 
personal relationship domain. In any domain, mean scores of serious and severe disease were 
always higher than mean scores of overall study population.  
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Graph 1 Mean score in six dimensions of DLQI for people with different disease severity 
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Graph 2 shows mean scores of total DLQI of different severity group and whole study population. 
Mean scores from different severity groups were significantly different (p<0.001). Mean score 
(±standard deviation) in severe disease was the highest (17.82±8.05), and was more than twice of 
the mean score in slight disease (8.10±7.0). Overall mean score in our study population was 
11.19±7.36.  
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Graph 2 Mean score of total DLQI for people with different disease severity 
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DISCUSSION 
Main findings 
The first aim of this study was to describe the characteristics in psoriasis patients in China and to 
compare the health related quality of life among the psoriasis patients who have different 
demographic, life style, and clinical factors. We found people with medical insurance, and 
severity higher than moderate level had larger proportion having worse quality of life. People in 
worse quality of life had significantly longer duration of disease. People who did not exercise 
regularly displayed a higher proportion of worse quality of life than people exercise regularly. 
The amount of people having worse quality of life was independent of age, gender, marital status, 
ethnicity, education level, income, BMI, age onset, comorbidities, smoking, and drinking.  
 
The second aim was to explore the relationship between demographic factors, life style factors, 
clinical factors, and the quality of life. Our findings were: having severity of disease was 
significantly associated with worse quality of life. People with serious disease had 3.5 times 
significantly higher risk of having worse quality of life. People with severe disease had 7.3 times 
significantly higher risk of having worse quality of life. Having medical insurance was associated 
with 1.6 higher risk have worse quality of life. Having exercise habit made patients 0.7 times less 
likely to have worse quality of life. There was no association between quality of life and age, 
gender, marital status, regions, ethnicity, educational level, BMI, age onset, duration of disease, 
comorbidities, smoking, and drinking habits.  
 
In addition, we observed when the severity degree was higher, overall quality of life and every 
aspect in quality of life had more reduction. 
  
!
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Compared with other studies 
We discovered that largely affected and less affected patients occupied almost equal proportion in 
our study population. This finding is not in line with previous studies done in single center 
settings in Malaysia (54) and in Germany (40) with the same DLQI cut-off 10, which have 
reported that people with less affected QOL considerably outnumber the largely affected. Perhaps 
this is because our multiple center design allowed us to recruit patients in more serious condition 
and healthcare accessibility in China is easier for the patients since transferal system from general 
physician to medical centers is not yet fully applied. Recruiting from inpatient department also 
resulted in such observation, as critical conditioned patients usually need hospital admission (55). 
Further analysis for our study population confirmed that amount of people with worse life quality 
was significantly higher (p<0.001) in inpatient department than outpatient department.  
 
Contrary to our finding, previous studies in other countries have revealed that women (55,56), 
younger age, lower income (58), living alone and lack of higher education (59) are correlated 
with worse quality of life. Such discrepancy might result from different cultural settings, different 
adjustment of confounding factors, and using different HRQOL instrument and different 
regression models. Previous studies use linear regression and adopt Psoriasis Disability Index 
(PDI) as outcome measure (55,58), which includes more specific questions regarding psoriasis 
per se than non-psoriasis specific DLQI. The questions are phrased with more clarity such as 
asking temporality of the behavioral changes. PDI widens the measuring time frame of patients’ 
feelings as “over the last four weeks”, suggesting it catches a more representative average 
condition of quality of life than DLQI, which only covers temporary quality of life “over the past 
week”. The loss of power because of dichotomization of DLQI and categorization of continuous 
variables (age, income) might also lead to such observation. Additionally, demographic factors 
only explain 2% of variance of overall quality of life in previous study (59), suggesting the 
influences of demographic factors are generally too weak to be detected.  
 
  
!
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We failed to reproduce the results from previous study that patients with early onset of psoriasis 
(<40 years old) has more psychological burden (60) due to the difficulties to express the negative 
emotion. Patients with onset before 20 years old also has been shown to be more vulnerable to 
the environmental stress (37). Personality traits are usually more stable after young adulthood 
(61), possibly explaining the lack of association of life quality and early onset defined as before 
40 years old in our study. In addition, the characteristics in Chinese society is hard to be 
comparative with western culture. Qualitative studies are needed to investigate the psoriasis 
stigmatization in Chinese cultural context. Literatures yield conclusions that longer disease 
duration does not necessarily build up psychological vulnerability (36) and possibly the patients 
become accustomed to living with the disease (57). Similarly, we observed the significance of 
disease duration in univariate analysis disappeared in the final model.  
 
Similar to our findings, higher severity has been confirmed as the most important determinant for 
lower quality of life in the previous cross-sectional study done in Malaysia (54) and a 
longitudinal study in Spain (56) but other studies suggest otherwise that severity and quality of 
life is poorly correlated (56,60). Our subjective physician global assessment might introduce 
interviewer bias and increase the variability of severity measurement than the standardized PASI. 
Besides, different studies have chosen different plethora of confounding factors into regression 
for adjustment and cross cultural difference of response in dermatology-specific HRQOL 
instrument is documented (63). Therefore, it is not surprising the result differed from one country 
to another.  
 
Smoking and alcohol consumption was not associated with worse quality of life in our study 
while previous reports suggest alcohol and smoking both exacerbate the psoriasis progression 
(64). The inability to exactly quantify the alcohol or cigarette consumption might generate this 
result. Alcohol and cigarette consumption strongly relied on questionnaire-based assessments and 
were subjected to recall bias. Selection bias in the study population might exist as well since the 
patients are inclined to quit smoking and alcohol drinking. Another possible reason is the intake 
amount we used to define the habitual behaviors was not strong enough to pose impact on quality 
of life. In line with our result, improvement of quality of life in psoriasis after physical activity 
intervention is documented (34,64). There is also a possible reverse causality that people might 
!
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refuse to exercise because of the itchy feeling or they might reduce the exercise frequency 
because of concerns about exposing their appearance.  
 
We are unable to provide a reasonable explanation as to why people who were covered by a 
medical insurance had worse quality of life. However, to obtain more understanding to this 
association, we probed further into DLQI question 10 “over the past week, how much trouble has 
the treatment for skin been, for example, by making your home messy or by taking up time?” We 
found people with medical insurance score significantly higher on this question than people 
without medical insurance (1.0±0.94 v.s. 1.2±0.98, p=0.003 in independent t test). This provides 
a possible explanation to our finding that un-measured confounding effect of treatment-related 
variables might lead to this result. Patients with medical insurance probably had more vigorous 
treatment or allowed them to seek care from multiple doctors, which generate poor quality of life 
due to additional inconvenience.  
 
Strengths and Limitations 
The study provides an overview of association or lack thereof between possible demographic 
factors, life style factors, clinical factors and quality of life in psoriasis patients. To our 
knowledge, this is the first large-scale hospital-based study aiming to explore the determinants 
for the quality of life in psoriasis patients in China. The large sample size (more than 1000 
participants) renders sufficient statistical power for the study.  
 
However, we acknowledge some of the study limitations.   
 
First, the dataset was originally designed for psychometric evaluation and item response theory 
test of various HRQOL questionnaires with a target population being individuals with any 
dermatological disease and not limited to psoriasis alone. Other confounders that exclusively 
could impact psoriasis-related quality of life were not available for more detailed investigation of 
clinical determinants in the HRQOL. For example, there is lack of subtype of psoriasis, under 
treatment or not for the past week, exact treatment ever been used or currently being used, 
multiple treatments or single treatment, joint and finger involvement, the magnitude of involved 
body areas, first visit to doctor or not, under flare-up episode or not, PASI score rather than 
!
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physician global assessment. Lack of these information made us unable to analyze on more 
specific psoriasis subgroups since daily functional disability would have been different if arthritis 
or finger nails were involved. Also, impact on outlook appearance depended on whether affected 
area was able to be concealed by clothes and whether the characteristics of the symptoms like 
flaking and eruption of pustule were extensively presented.  
 
Second, the multiple effects that demographic variables impose on quality of life might not be 
encapsulated in statistical models. Most variables do not have a specific way to be conceptualized 
in causal relationship and makes it difficult to generate a definitive priori hypothesis. For 
example, effect of being a woman on quality of life mediated by social stigma is negative, but 
effect of being a woman on quality of life mediated by more awareness on treatment is positive. 
These effects might cancel each other and produce the overall non-significant association in 
statistical model. Further, complex interplay of variables related to quality of life prohibits us to 
make a thorough interpretation of association. For instance, BMI is related to disease severity and 
directly affects self-esteem and produce worse quality of life, but BMI is also a mediator in 
between exercises and quality of life. Moreover, in this study we didn't take interaction terms and 
multi-collinearity into consideration while these phenomena may exist between several variables 
(eg. age at onset and duration of disease). A more comprehensive analysis and temporality of 
variables are needed to solve these problems.  
 
Third, variables are subjected to recall bias. Since participants answered whether having smoking, 
drinking, and exercise habits based on their own liberal judgment, it is possible that they were not 
honest about the frequency and quantity of the habits. Furthermore, the definition of variables 
was restricted due to availability of data. Low frequency of daily drinker (only 24 people reported 
drink daily) and omission of alcohol consumption amount (1/4 of self-claimed drinker didn’t 
report the intake amount) made us refer to a habitual drinking definition that is actually within 
recommended amount (66). These biases and practical limitations are perhaps the reasons for the 
association we observed. In addition, variables might not reflect the circumstances in real life. 
Medical insurance type was a single choice during data collection while in reality a person can 
have multiple medical insurances or registered as un-insured in residence province while being 
insured in another province. Such negligence in data collection complicated our interpretation.  
!
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Fourth, evidences on validity of original English version of DLQI are conflicting. The extensive 
literatures using DLQI as HRQOL measurement and well-documented score interpretation are 
the main reasons we selected DLQI out of 3 other HRQOL measurements in the dataset. 
However, although it is true that DLQI has been used in dermatological clinical trial and clinical 
survey for more than 20 years, the popularity of DLQI in dermatology might be only due to its 
simplicity and convenience to provide a rough perspective of quality of life, instead of its 
structural design or accuracy for measuring health related quality of life. In previous literature 
(67), DLQI has shown well property testing results in Classical Test Theory, such as internal 
consistency, test-retest reliability, content validity, and construct validity, but the sensitivity test 
is rarely examined. Floor effect and ceiling effect of DLQI has been demonstrated (68), 
suggesting that difference of responses from the studied individuals might not reflect on the 
scores of our outcome measure. The questions in DLQI highly focus on function disability and 
very few on individual emotion. Each domain in DLQI contains only too few items, suggesting 
total score of DLQI didn’t fully encapsulate the notion in mental health. Furthermore, recent 
research using Item Response Theory and Rasch analysis unveiled several problems and concerns 
about the structure of DLQI (62,63). One of the obvious problems is the difficulties to 
differentiate options “a lot” and “very much” because they are conceptually similar. Another 
issue is that, according to scoring guideline (Appendix B), “not relevant” responses are scored 0, 
just the same as “not at all” responses. By following the scoring guideline, we possibly 
misclassified people as having better quality of life when they actually were in worse quality of 
life. The DLQI developer claimed DLQI has single construct which failed to be confirmed by 
statistical methods, and the questions in DLQI cover physical, emotional, functional, and social 
disability, which are hardly a single construct intuitively. As the psychometric evaluation is 
evolving, it is not surprising that DLQI as the first generation of dermatology QoL instrument, 
has failed to meet the newer standard of validation, despite the fact the confirmed validity in 
Classical Test Theory (71). As for the validity of Chinese version of DLQI, it passed the 
construct validity test by performing known group comparison, spearman correlation with other 
HRQOL instruments, and confirmatory factor analysis (42). However, content validity, test-retest 
reliability (repeatability) and responsiveness are not yet examined for Chinese version of DLQI. 
A lot more could be done to ensure the validity of Chinese version of DLQI. 
!
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Future research  
As economy in China is in rapid growth, the balance of productivity and general well-being 
becomes more essential. As critical skin disease like psoriasis imposes tremendously negative 
effects on daily life, the continued effort is needed to strengthen the knowledge about psoriasis 
patients’ quality of life. The future studies should collect more possible predictors for quality of 
life, especially those clinical-related, with more careful definition. Incorporating the information 
from hospital database is an option to obtain more details about clinical history. Including more 
variables that have straightforward confounding effect and causal effect is essential, such as 
temperature, humidity, experiencing stigmatization, under which treatment, etc. Besides, the 
instruction of administration of questionnaire should be emphasized to ensure the completeness 
of data. The longitudinal design is absolutely needed to solve the reverse causality problem and 
comparison with people without psoriasis should be considered. A closer look into other HRQOL 
measure, such as Skindex and WHOQOL, could provide a clear picture of HRQOL in psoriasis. 
A well-structured Health Related Quality of Life tool is needed for psoriasis. Item response 
theory should be harnessed in the validity test when constructing a new instrument. Future study 
could focus on multiple hospitals from urban and rural areas in single province with longer 
duration of data collection. A different clinical setting is another research option, for example in 
hospitals only offering western medicine or primary clinics. Analyzing on specific subtype of 
psoriasis or specific age group would be another interesting topic.   
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CONCLUSIONS AND RECOMMENDATIONS 
Our findings establish the needs to incorporate the quality of life assessment in the healthcare for 
adult psoriasis patients in China. Larger proportion of poor quality of life was observed in people 
with medical insurance, in patients with higher degree of severity, and in patients without 
exercise habit. Likewise, statistically significant probability for poor quality of life was identified 
for severe and serious psoriasis, patients with medical insurance, and patients without exercise 
habit. These findings provide some insights about the target areas in public health measures. 
Policy makers should place controlling psoriasis severity as priority and put burden of treatment 
from medical insurance into perspective. Attention must be paid on improving the physical 
inactivity in psoriasis patients. The disease burden in China is amplified through the rapid growth 
of economy and population. Implementing an overarching policy for psoriasis patients in this 
country is imperative. More research should be done to address the risk factors for quality of life 
impact for patients in China to achieve a multilateral management of psoriasis.   
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APPENDIX A DERMATOLOGY LIFE QUALITY INDEX 
Hospital No.                                                                                                                             Date: 
Name 
Address                                                                                                                                     Diagnosis 
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK.  
Please tick one box for each question. 
 
1 Over the last week, how itchy, sore, painful or 
stinging has your skin been? 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
 
2 Over the last week, how embarrassed or self-
conscious have you been because of your skin? 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
 
3 Over the last week, how much has your skin 
interfered with you going shopping or looking 
after your home or garden? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
  
4 Over the last week, how much has your skin 
influenced the clothes you wear? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
  
5 Over the last week, how much has your skin 
affected any social or leisure activities? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
 
6 Over the last week, how much has your skin 
made it difficult for you to do any sport? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
  
7 Over the last week, has your skin prevented you 
from working or studying? 
Yes 
No                   
  
❒ 
❒ 
 
Not relevant ❒  
 If "No", over the last week how much has your 
skin been a problem at work or studying? 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
 
 
8 Over the last week, how much has your skin 
created problems with your partner or any of your 
close friends or relatives? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
 
9 Over the last week, how much has your skin 
caused any sexual difficulties? 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
  
10 Over the last week, how much of a problem has 
the treatment for your skin been, for example by 
making your home messy, or by taking up time? 
 
Very much 
A lot 
A little 
Not at all 
❒ 
❒ 
❒ 
❒ 
Not relevant ❒ 
 
 
Please check you have answered EVERY question. Thank you.  
 ©AY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors. 
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APPENDIX B Instructions for use of Dermatology Quality of Life Index 
 
Dermatology Life Quality Index (DLQI) 
The Dermatology Life Quality Index questionnaire is designed for use in adults, i.e. patients over the 
age of 16. It is self explanatory and can be simply handed to the patient who is asked to fill it in 
without the need for detailed explanation. It is usually completed in one to two minutes. 
 
Scoring 
The scoring of each question is as follows: 
 
Response Score 
Very much scored 3 
A lot scored 2 
A little scored 1 
Not at all scored 0 
Not relevant scored 0 
Question unanswered scored 0 
Question 7: “prevented work or studying” scored 3 
 
 
The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a 
minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be 
expressed as a percentage of the maximum possible score of 30. 
**Please Note: That the scores associated with the different answers should not be printed on the 
DLQI itself, as this might cause bias** 
 
Meaning of DLQI Scores 
0-1 = no effect at all on patient’s life 
2-5 = small effect on patient’s life 
6-10 = moderate effect on patient’s life 
11-20 = very large effect on patient’s life 
21-30 = extremely large effect on patient’s life 
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Detailed analysis of the DLQI 
The DLQI can be analysed under six headings as follows:  
 
Section Questions Score 
Symptoms and feelings Questions 1 and 2 Score maximum 6 
Daily activities Questions 3 and 4 Score maximum 6 
Leisure Questions 5 and 6 Score maximum 6 
Work and School Question 7 Score maximum 3 
Personal relationships Questions 8 and 9 Score maximum 6 
Treatment Question 10 Score maximum 3 
 
The scores for each of these sections can also be expressed as a percentage of either 6 or 3. 
 
(Continued) 
Interpretation of incorrectly completed questionnaires 
There is a very high success rate of accurate completion of the DLQI. However, sometimes subjects 
do make mistakes. 
1. If one question is left unanswered this is scored 0 and the scores are summed and expressed as 
usual out of a maximum of 30. 
2. If two or more questions are left unanswered the questionnaire is not scored. 
3. If question 7 is answered ‘yes’ this is scored 3. If question 7 is answered ‘no’ but then either ‘a lot’ 
or ‘a little’ is ticked this is then scored 2 or 1. If “Not relevant” is ticked, the score for Question 7 is 0. 
If it is answered ‘no’, but the second half is left incomplete, the score will remain 0. 
4. If two or more response options are ticked, the response option with the highest score should be 
recorded. 
5. If there is a response between two tick boxes, the lower of the two score options should be 
recorded. 
6. The DLQI can be analysed by calculating the score for each of its six sub-scales (see above). When 
using sub-scales, if the answer to one question in a sub-scale is missing, that sub-scale should not be 
scored. 
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Minimal Clinically Important Difference of the DLQI 
For general inflammatory skin conditions a change in DLQI score of at least 4 points is considered 
clinically important (Basra et al, 2015, see below). This means that a patient’s DLQI score has to 
either increase or decrease by at least 4 points in order to suggest that there has actually been a 
meaningful change in that patient’s quality of life since the previous measurement of his/her DLQI 
scores. 
  
!
!
!
40 
APPENDIX C Mean scores of DLQI from different severity groups and overall study population. (S.D is standard deviation) 
 
 
Maximum on the 
subscale severe (n=28) S.D. serious (n=229) S.D. 
Moderate 
(n=654) S.D. mild (n=272) S.D. slight (n=29) S.D. overall S.D. 
Symptoms and 
feelings 6 3.57 1.75 3.11 1.61 2.61 1.45 2.29 1.34 2.1 1.69 2.66 1.52 
Daily activities  6 4.14 1.64 2.95 1.93 2.28 1.71 1.82 1.62 1.83 1.64 2.33 1.80 
Leisure  6 3.39 1.98 2.78 1.86 2.13 1.59 1.63 1.57 1.59 1.64 2.17 1.72 
Work and school  3 2.1 1.03 1.53 1.18 1.24 1.1 0.9 0.99 0.55 0.78 1.24 1.12 
Personal 
relationship  6 2.89 2 2.15 1.91 1.63 1.62 1.08 1.39 1.24 1.59 1.62 1.68 
Treatment burden 3 1.71 1.21 1.49 1.04 1.16 0.93 0.89 0.88 0.79 0.9 1.17 0.98 
Total 30 17.82 8.05 14.02 8.18 11.06 6.87 8.6 6.26 8.1 7 11.19 7.33 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
